DARA + pom-dex for R/R multiple myeloma

Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer InstituteПодробнее

Multiple Myeloma - Case PresentationsПодробнее

ICARIA study: Isatuximab and pom/dex for multiple myelomaПодробнее

Pom/dex combinations as salvage for myeloma R/R to daraПодробнее

Clinical Trial: Darzalex (daratumamab) with Revlimid/Velcade/Dex for Newly Diagnosed MyelomaПодробнее

Alliance A061202: POM-DEX vs IXA-POM-DEX in R/R multiple myelomaПодробнее

Pomalidomide + Low-Dose Dex + Dara in Relapsed and/or Refractory Multiple MyelomaПодробнее

Investigating the efficacy of twice weekly ixazomib plus pom-dex in R/R multiple myelomaПодробнее

Daratumumab in combination with carfilzomib and dex in len-refractory patients with RMMПодробнее

DARE: dara for R/R myeloma with renal impairmentПодробнее

DARIA: second-line dara plus ixazomib and dex in len-refractory myeloma patientsПодробнее

MRD negativity rates following carfilzomib, dex & dara in R/R myelomaПодробнее

R/R myeloma: iberdomide, dex & dara or bortezomibПодробнее

Melflufen/dex versus pom/dex in patients with R/R multiple myeloma without previous transplantПодробнее

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMMПодробнее

MAIA: dara-len-dex demonstrates prolonged PFS in multiple myelomaПодробнее

The promise of pomalidomide-backbone combinations for R/R multiple myelomaПодробнее

DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myelomaПодробнее

Carfilzomib 2x Weekly in Combination with Dex and Daratumumab Vs Dara with Bortezomib and DexПодробнее